Drugs / YY201
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06225856 | Oct 2023 → Dec 2026 expected | hematopoietic and lymphoid cell neoplasm | Shanghai Yuyao Biotech Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT03240939 | Mar → Jul 2017 | benign prostatic hyperplasia | Yuyu Pharma, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YY201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06225856 ↗ |
| Route | Oral | “Oral administration under fasting state.” NCT06225856 ↗ |